News/announcements

 

Directorate Change

Bioquell PLC (the “Company”) announces that Nigel Keen has informed the Company that he will be retiring at the end of the AGM which is to be held on 10 June, 2016.
Mr. Keen will be succeeded as non-executive Chairman by Ian Johnson who is being appointed to the Board today and who has been put forward for election as a director of the Company at the forthcoming AGM.
Mr Johnson has spent his career working in a number of Life Sciences companies and is currently non-executive chairman of Cyprotex PLC and was formerly non-executive chairman of Celsis International Group as well as a non-executive director of MyCelx Technologies Corporation. 

Read more

Tender Offer Circular

Proposed Return of Cash to Shareholders of Bioquell PLC by way of a Tender Offer to purchase 1 in every 2 Ordinary Shares held by Qualifying Shareholders at a tender price of £2.00 per Ordinary Share and Notice of General Meeting.

Read more

Tender Offer

Tender Offer

Further to the Board’s announcement on 29 April 2016, the Company announces a tender offer pursuant to which 1 in every 2 Ordinary Shares held by Qualifying Shareholders would be purchased at a price of £2 per Ordinary Share. If the maximum number of shares under the Tender Offer is acquired, this will result in an amount of approximately £44 million being returned by the Company to Qualifying Shareholders.
A circular including notice of the General Meeting and a tender offer application form is expected to be sent to Shareholders later today and will set out the background to and reasons for the Tender Offer and why the Directors believe the Tender Offer to be in the best interests of the Company and its Shareholders as a whole. The Circular will also contain details on the procedure that should be followed by those Qualifying Shareholders who wish to participate in the Tender Offer. The Company is seeking Shareholders’ approval of the Tender Offer at a General Meeting to be held at 12.00 p.m. on 20 June 2016.
 
As set out in further detail within the Circular, whilst the Board is engaged in preliminary discussions with several parties regarding a potential offer for the Company, Shareholders should be aware that these discussions are at an early stage and there can be no certainty that an offer will be made, nor as to the terms on which any offer might be made. Shareholders should note that the Board considers it unlikely that, in the event that an offer for the Company is received, it will be at a price per share which is greater than the Tender Price. The Board will announce further details of these discussions as appropriate.
 

Read more

Notice of AGM 2016

Notice of AGM 2016

The Annual General Meeting (“AGM”) of Bioquell PLC (“Bioquell” or “the Company”) will take place on Friday 10 June 2016 at the Company’s offices, 52 Royce Close, West Portway, Andover, Hampshire, SP10 3TS. The Meeting will start at 12.00 noon.

Read more

Posting of Annual Report & Notice of AGM

Bioquell PLC, confirms that the Annual Report and Accounts for the year ended 31 December 2015, the Notice of the Annual General Meeting and a Form of Proxy are available on the Company’s website: www.bioquellplc.com.

Read more

Dissemination statement April 2016

Bioquell PLC
Dissemination statement
Following the preliminary announcement issued this morning (29 April 2016), the full electronic version of the BIOQUELL annual report is now available to download in PDF format on the Company’s website at http://www.bioquellplc.com.
Hard copies of the annual report will be mailed to BIOQUELL shareholders on the register as at today’s date.

Read more

Intention to return approximately £42.7 million to Bioquell shareholders by way of a tender offer Anticipated tender offer terms

Intention to return approximately £42.7 million to Bioquell shareholders by way of a tender offer
Anticipated tender offer terms: £2 per Share in respect of 50% of the issued Share capital
 
The Board of Bioquell PLC (“Bioquell” or the “Company”) announces that it has concluded that it would be helpful for the Strategic Review process and in the best interests of Bioquell shareholders (“Shareholders”) if a substantial proportion of the cash currently on the Company’s balance sheet were returned to Shareholders by way of tender offer.

Read more

Bioquell PLC announces its 2015 preliminary results

Bioquell PLC (LSE symbol: BQE), the provider of specialist microbiological control technologies to the international Healthcare, Life Science and Defence markets today announces its 2015 preliminary results.
Unless otherwise indicated, all financial information set out in this document relates to continuing activities and does not include any contribution from TRaC Global Limited (“TRaC”), the sale of which completed on 7 May, 2015.
 

Read more

Bioquell PLC Strategic Review update 13 April 2016

Bioquell PLC

Strategic Review update

Further to the announcement made on 14 January 2016, the Strategic Review announced on 18 May 2015 is ongoing and consequently the Company remains in an offer period under the framework provided by a formal sales process under the Takeover Code. The Company will publish its results for the year ended 31 December 2015 before the end of April.
 
Ends
 
 
Enquiries:
 
Bioquell PLC     
Tel: 01264 835 900
 
Nicholas Adams - Group Chief Executive
Michael Roller - Finance Director
Georgina Pope - Company Secretary
 

Read more

Bioquell PLC Pre-close statement 14 January, 2016

Bioquell PLC ("Bioquell") (LSE symbol: BQE) - provider of specialist microbiological control technologies to the international Healthcare, Life Sciences & Defence markets today announces an update on its trading performance, prior to entering the closed period ahead of the preliminary results for the year to 31 December 2015.
Trading since the release of the interim results on 26 August 2015 has remained broadly consistent with the Board’s expectations.

Read more